Stock Events

Stock Events

Aprea Therapeutics 

$0.7943
39
-$0.01-1.49% Friday 20:00
+$0.01+1.72%Friday 23:58After hours

Statistics

Day High
0.805
Day Low
0.795
52W High
1.69
52W Low
0.548
Volume
4,206
Avg. Volume
-
Mkt Cap
10M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.71
-0.5
-0.28
-0.06
Expected EPS
-0.065
Actual EPS
N/A

Financials

-4,405.59%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
286,000Revenue
-12.6MNet Income

Analyst Ratings

3.07Average Price Target
The highest estimate is 5.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow APRE. It's not an investment recommendation.
Microsoft
6
MSFT
Coca-Cola
5
KO
Intel
5
INTC
SoFi Technologies
5
SOFI

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences focuses on oncology, HIV/AIDS, liver diseases, and other areas, directly competing in the cancer treatment space with Aprea Therapeutics.
AMGEN
AMGN
Mkt Cap236.38B
Amgen operates in the biotechnology field focusing on human therapeutics, including treatments for cancer, which competes with Aprea's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines for cancer and other diseases, making it a direct competitor.
Pfizer
PFE
Mkt Cap162.16B
Pfizer engages in the discovery, development, and manufacture of healthcare products including oncology drugs, competing in the same market as Aprea.
Merck
MRK
Mkt Cap370.89B
Merck is known for its high-quality cancer treatments and research in oncology, positioning it as a competitor in the cancer therapy market.
Novartis
NVS
Mkt Cap304.1B
Novartis focuses on patented medicines for a range of diseases, including cancer, directly competing with Aprea in the oncology sector.
Roche
RHHBY
Mkt Cap334.28B
Roche operates in pharmaceuticals and diagnostics with a strong emphasis on oncology, making it a competitor in cancer treatment.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie works in the discovery, development, and marketing of both biopharmaceuticals and small molecule drugs, including oncology, competing with Aprea.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in several key therapeutic areas including oncology, making it a competitor in the development of cancer treatments.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly and Company focuses on pharmaceuticals in oncology and other areas, competing with Aprea in the cancer treatment market.

About

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Show more...
CEO
Oren Gilad
Employees
8
Country
United States
ISIN
US03836J2015

Listings

XNAS
US
APRE
BOATS
BOATS
APRE.BOATS

0 Comments

Share your thoughts

FAQ

What is Aprea Therapeutics stock price today?▼
The current price of APRE is $0.79 USD — it has decreased by -1.49% in the past 24 hours. Watch Aprea Therapeutics stock price performance more closely on the chart.
What is Aprea Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Aprea Therapeutics stocks are traded under the ticker APRE.
Is Aprea Therapeutics stock price growing?▼
APRE stock has fallen by -0.71% compared to the previous week, the month change is a +22.14% rise, over the last year Aprea Therapeutics has showed a -48.75% decrease.
What is Aprea Therapeutics market cap?▼
Today Aprea Therapeutics has the market capitalization of 10M
When is the next Aprea Therapeutics earnings date?▼
Aprea Therapeutics is going to release the next earnings report on November 05, 2026.
What were Aprea Therapeutics earnings last quarter?▼
APRE earnings for the last quarter are -0.07 USD per share, whereas the estimation was -0.18 USD resulting in a +60.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aprea Therapeutics revenue for the last year?▼
Aprea Therapeutics revenue for the last year amounts to 286,000 USD.
What is Aprea Therapeutics net income for the last year?▼
APRE net income for the last year is -12.6M USD.
How many employees does Aprea Therapeutics have?▼
As of September 07, 2026, the company has 8 employees.
In which sector is Aprea Therapeutics located?▼
Aprea Therapeutics operates in the Health & Wellness sector.
When did Aprea Therapeutics complete a stock split?▼
The last stock split for Aprea Therapeutics was on February 13, 2023 with a ratio of 1:20.
Where is Aprea Therapeutics headquartered?▼
Aprea Therapeutics is headquartered in DOYLESTOWN, United States.